Terms: = Skin cancer AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2 AND Clinical Outcome
13 results:
1. Prognostic biomarkers for survival in mucosal melanoma.
Thierauf JC; Kaluziak ST; Codd E; Dybel SN; Jobbagy S; Purohit R; Farahani AA; Dedeilia A; Naranbhai V; Hoang MP; Fisch AS; Ritterhouse L; Boland GM; Lennerz JK; Iafrate AJ
Pigment Cell Melanoma Res; 2023 Sep; 36(5):378-387. PubMed ID: 37390098
[TBL] [Abstract] [Full Text] [Related]
2. Clinicogenomic associations in childhood Langerhans cell histiocytosis: an international cohort study.
Kemps PG; Zondag TCE; Arnardóttir HB; Solleveld-Westerink N; Borst J; Steenwijk EC; van Egmond D; Swennenhuis JF; Stelloo E; Trambusti I; Verdijk RM; van Noesel CJM; Cleven AHG; Scheijde-Vermeulen MA; Koudijs MJ; Krsková L; Hawkins C; Egeler RM; Brok J; von Bahr Greenwood T; Svojgr K; Beishuizen A; van Laar JAM; Pötschger U; Hutter C; Sieni E; Minkov M; Abla O; van Wezel T; van den Bos C; van Halteren AGS
Blood Adv; 2023 Feb; 7(4):664-679. PubMed ID: 36083130
[TBL] [Abstract] [Full Text] [Related]
3. Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306).
Holch JW; Held S; Stintzing S; Fischer von Weikersthal L; Decker T; Kiani A; Kaiser F; Heintges T; Kahl C; Kullmann F; Scheithauer W; Moehler M; von Einem JC; Michl M; Heinemann V
Ann Oncol; 2020 Jan; 31(1):72-78. PubMed ID: 31912799
[TBL] [Abstract] [Full Text] [Related]
4. Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations.
Cosgarea I; Ugurel S; Sucker A; Livingstone E; Zimmer L; Ziemer M; Utikal J; Mohr P; Pfeiffer C; Pföhler C; Hillen U; Horn S; Schadendorf D; Griewank KG; Roesch A
Oncotarget; 2017 Jun; 8(25):40683-40692. PubMed ID: 28380455
[TBL] [Abstract] [Full Text] [Related]
5. On-treatment markers as predictors to guide anti-EGFR MoAb treatment in metastatic colorectal cancer: a systematic review with meta-analysis.
Hu J; Zhang Z; Zheng R; Cheng L; Yang M; Li L; Liu B; Qian X
Cancer Chemother Pharmacol; 2017 Feb; 79(2):275-285. PubMed ID: 27878357
[TBL] [Abstract] [Full Text] [Related]
6. Is biomarker research advancing in the era of personalized medicine for head and neck cancer?
Yokota T
Int J Clin Oncol; 2014 Apr; 19(2):211-9. PubMed ID: 24442754
[TBL] [Abstract] [Full Text] [Related]
7. Controversies in antiepidermal growth factor receptor therapy in metastatic colorectal cancer.
Woo J; Palmisiano N; Tester W; Leighton JC
Cancer; 2013 Jun; 119(11):1941-50. PubMed ID: 23504768
[TBL] [Abstract] [Full Text] [Related]
8. Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study.
Van Cutsem E; Tejpar S; Vanbeckevoort D; Peeters M; Humblet Y; Gelderblom H; Vermorken JB; Viret F; Glimelius B; Gallerani E; Hendlisz A; Cats A; Moehler M; Sagaert X; Vlassak S; Schlichting M; Ciardiello F
J Clin Oncol; 2012 Aug; 30(23):2861-8. PubMed ID: 22753904
[TBL] [Abstract] [Full Text] [Related]
9. Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction.
Wainberg ZA; Lin LS; DiCarlo B; Dao KM; Patel R; Park DJ; Wang HJ; Elashoff R; Ryba N; Hecht JR
Br J Cancer; 2011 Sep; 105(6):760-5. PubMed ID: 21811258
[TBL] [Abstract] [Full Text] [Related]
10. Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to kras and BRAF mutational status.
Fornaro L; Baldi GG; Masi G; Allegrini G; Loupakis F; Vasile E; Cupini S; Stasi I; Salvatore L; Cremolini C; Vincenzi B; Santini D; Tonini G; Graziano F; Ruzzo A; Canestrari E; Magnani M; Falcone A
Crit Rev Oncol Hematol; 2011 Jun; 78(3):243-51. PubMed ID: 20619672
[TBL] [Abstract] [Full Text] [Related]
11. Immunoglobulin G fragment C receptor polymorphisms and kras mutations: are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy?
Paez D; Paré L; Espinosa I; Salazar J; del Rio E; Barnadas A; Marcuello E; Baiget M
Cancer Sci; 2010 Sep; 101(9):2048-53. PubMed ID: 20550522
[TBL] [Abstract] [Full Text] [Related]
12. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab.
Lurje G; Nagashima F; Zhang W; Yang D; Chang HM; Gordon MA; El-Khoueiry A; Husain H; Wilson PM; Ladner RD; Mauro DJ; Langer C; Rowinsky EK; Lenz HJ
Clin Cancer Res; 2008 Dec; 14(23):7884-95. PubMed ID: 19047118
[TBL] [Abstract] [Full Text] [Related]
13. Kaposi's sarcoma of the pancreas mimicking pancreatic cancer in an HIV-infected patient. clinical diagnosis by detection of HHV 8 in bile and complete remission following antiviral and cytostatic therapy with paclitaxel.
Menges M; Pees HW
Int J Pancreatol; 1999 Dec; 26(3):193-9. PubMed ID: 10732297
[TBL] [Abstract] [Full Text] [Related]
